ABLYNX (OTCMKTS:ABLYF) is scheduled to issue its quarterly earnings data after the market closes on Thursday, February 22nd. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.
Shares of ABLYNX (OTCMKTS:ABLYF) opened at $54.50 on Tuesday. ABLYNX has a 52 week low of $11.10 and a 52 week high of $54.75.
ABLYF has been the topic of several recent research reports. Zacks Investment Research upgraded ABLYNX from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Wednesday, November 22nd. Bank of America initiated coverage on ABLYNX in a research note on Friday, November 10th. They issued a “buy” rating and a $26.00 price target on the stock. Finally, ValuEngine upgraded ABLYNX from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd.
TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/20/ablynx-ablyf-set-to-announce-quarterly-earnings-on-thursday.html.
Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.
Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.